Real-world data results:

Switching to Velphoro made a world of difference

Full results below

Double the percentage of patients achieved goal with half the pill burden1

Recently published real-world data shows 6 months after switching to Velphoro, significantly more patients achieved KDOQI goal, with half the pill burden.

fewer pills per day

Consider a different approach to phosphorus management

Study design

A retrospective analysis of pharmacy data assessed the real-world effectiveness of Velphoro in 1,029 adult in-center hemodialysis patients who were switched to Velphoro during routine care between April 2014 through March 2015. The blinded study compared the proportion of patients with phosphorus levels <5.5 mg/dL and the mean prescribed PB pills/day at baseline (3 months prior to Velphoro) and during Velphoro follow-up (6 months after switch to Velphoro, n=424). This was a non-interventional analysis and did not impact prescriptions or prescribing patterns.

Regardless of prior therapy, a switch to Velphoro doubled the percentage of patients who achieved goal at 6 months.1

Create a world of difference for your patients with a switch to Velphoro

Read the details of this real world data analysis on phosphorus control and reduced pill burden with Velphoro

Read the article

Velphoro is flexible and affordable for your patients

pill icon

Flexible Administration2

Starting dose of 1 tablet per meal. Easy to chew and
easy to crush.2

See the options
access icon

Velphoro Access Solutions

Coverage is available on most national Medicare Part D and commercial plans.

Learn more

Reference:

  1. Coyne DW, Ficociello LH, Parameswaran V, et al. Real-world effectiveness of sucroferric oxyhydroxide in patients on chronic hemodialysis: A retrospective analysis of pharmacy data. Clin Nephrol. 2017;88(2):59-67.
  2. Velphoro® [package insert]. Waltham, MA: Fresenius Medical Care North America; 2018.

INDICATION

Velphoro® (sucroferric oxyhydroxide) is a phosphate binder indicated for the control of serum phosphorus levels in patients with chronic kidney disease on dialysis.

IMPORTANT SAFETY INFORMATION

For additional important safety information, please see the full Prescribing Information.

To report SUSPECTED ADVERSE REACTIONS, contact Fresenius Medical Care North America at
1-800-323-5188 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

This information is intended for use by US healthcare professionals only.
 

Distributed by:
Fresenius Medical Care North America
Waltham, MA 02451